sofosbuvir and ledipasvir (Harvoni®)

ORAL ADMINISTRATION

Indications for Prior Authorization:

  • Treatment of chronic hepatitis C, genotype 1, 4, 5, 6 - with or without Ribavirin per FDA approved dosing.

All of the following must be met as a condition for coverage:

  • Patient must have compensated liver disease by fibroscan ultrasound or biopsy, documenting stage 2, 3 or stage 4.  Acitest-Fibrotest is not accepted as documentation.
  • Patient must have FDA recognized contraindication to use of Zepatier® (for Genotype 1 or 4)
  • Resistance testing must be included with the prior authorization request for genotype 1.
    • Treatment failure associated with HCV resistance to newly developed direct-acting antiviral agents is not an uncommon occurrence and poses a substantial problem to clinicians trying to re-treat patients who have failed available interferon-free treatments.

This Medication is Not Approvable for the following condition(s):

  • Patients with Stage 0 or Stage 1 fibrosis
  • Patients who have failed/relapsed on sofosbuvir plus simeprevir or ribavirin
  • Any condition not listed above as an approved indication

Duration of Therapy:

Fibrosis

  • Stage 1 none or mild peri-portal fibrosis – not approvable
  • Stage 2 peri-portal fibrosis with/without extension and portal-portal bridging – approvable
  • Stage 3 portal-central bridges but no nodular formation - approvable
  • Stage 4 definite cirrhosis – approvable
  • Treatment naïve stage 3, viral load less than 6 M IU   8 weeks
  • Treatment naïve stage 3, viral load greater than 6 M IU or stage 4  12 weeks
  • Treatment failure* stage 3   12 weeks
  • Treatment failure* stage 4  24 weeks

Dosing:

  • Genotype 1, treatment-naive without cirrhosis or with compensated cirrhosis (Child-Pugh class A) - Harvoni (90 mg/400 mg)  daily for 12 weeks.
  • Genotype 1, treatment-experienced without cirrhosis - Harvoni (90 mg/400 mg) daily for 12 weeks.
  • Genotype 1, treatment-experienced with compensated cirrhosis (Child-Pugh class A) - Harvoni (90 mg/400 mg) daily for 24 weeks.
  • Genotype 1, treatment-experienced with decompensated cirrhosis (Child-Pugh class B or C) - Harvoni (90 mg/400 mg) once daily for 12 weeks in combination with ribavirin.
  • Genotype 1 or 4 - treatment-naive and treatment-experienced liver transplant recipients without cirrhosis, or with compensated cirrhosis (Child-Pugh class A) - Harvoni (90 mg/400 mg) once daily for 12 weeks in combination with ribavirin.
  • Genotype 4, 5, or 6 - treatment-naive and treatment-experienced without cirrhosis or with compensated cirrhosis (Child-Pugh class A) - Harvoni (90 mg/400 mg) once daily for 12 weeks.
  • *Treatment failure/relapse with non-sofosbuvir drug regimens

 

Last review date: March 2, 2015

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.

Press Esc to cancel

El sitio Web al que está siendo transferido no es provisto por WHA. Las Condiciones de Uso y las Prácticas de Privacidad en Internet de WHA no se aplican a este sitio Web asociado que usted está usando. Revise las políticas sobre la privacidad y condiciones de uso de este sitio Web asociado. WHA no tiene control sobre la exactitud, la totalidad o la actualidad del contenido del sitio Web asociado. WHA no puede garantizar que los servicios de traducción de idiomas estarán disponibles en el sitio vinculado.

Presione «Esc» para cancelar